Telix Pharmaceuticals
Telix Pharmaceuticals is seeking a Quality Assurance Associate to support the international roll-out of its prostate cancer imaging agent and advance its portfolio of late clinical-stage products. The role involves ensuring GxP conformity and compliance with quality management systems at the Angleton manufacturing site, focusing on operational activities. The associate will collaborate with cross-functional teams to support batch review, release activities, and continuous improvement of the quality management system.
Headquarters
North Melbourne, Victoria, Australia
Company Size
201-500 employees
Founded
2015
Telix Pharmaceuticals is a global, commercial‑stage biopharmaceutical company developing diagnostic and therapeutic “theranostic” products that use targeted radiation to detect and treat cancer. It advances radiopharmaceuticals through clinical development, regulatory approval, manufacturing and commercialisation to bring imaging agents and targeted therapies to patients. Telix works with the nuclear medicine community and international partners to scale access and improve outcomes. Its stated mission is to help patients with cancer live longer with better quality lives.
TLX DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Telix Pharmaceuticals
Dec 14, 2025
Telix Pharmaceiuticals sees sell-off on back of class actions | ASX:TLX
Nov 13, 2025
Pharma groups rush to calm investor fears over Trump’s tariff hit
Sep 26, 2025
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Telix Pharmaceuticals.
Telix Pharmaceuticals didn’t post a salary, so this is our estimate from similar listings.
The Market Doesn't Like What It Sees From Telix Pharmaceuticals Limited's (ASX:TLX) Revenues Yet As Shares Tumble 26%
Dec 31, 2025